Maximizing nutrition in smaller portions
A new class of medications is reshaping how people manage both type 2 diabetes and obesity. GLP-1 receptor agonists —including Ozempic, Wegovy, and similar drugs— were originally developed to help regulate blood sugar, but their potent effects on appetite suppression and weight loss have fueled a surge in global use.
GLP-1 drugs mimic a natural hormone (glucagon-like peptide-1) that slows digestion, stimulates insulin release, and signals fullness to the brain.[1] Together, these mechanisms help lower blood sugar and promote weight loss by leading patients to eat substantially less.
Today, millions of people are turning to these drugs not only to improve metabolic health, but also to support medically supervised, sustainable weight management. Alongside this success, an important nutritional challenge is emerging: as appetite decreases and portion sizes shrink, satisfying nutritional needs becomes more difficult.
When food intake drops, nutritional quality becomes more important than ever. A recent study[2] found that people taking GLP-1 medications frequently fall short of recommended daily intakes for several essential nutrients, including fiber, calcium, magnesium, potassium, iron, choline, and vitamins A, C, D, and E.
This is where nuts and dried fruits offer a strategic advantage. Naturally nutrient-rich and calorie-efficient, they pack a wide range of vitamins, minerals, healthy fats, and plant-based proteins into small, satisfying portions. This makes them ideal for people eating less but needing more nutrition per bite.
In a recent article in the American Journal of Clinical Nutrition,[3] researchers urged clinicians to help patients on GLP-1 drugs optimize their nutrition by focusing on nutrient-dense, minimally processed foods —including nuts, fruits, and legumes, in addition to vegetables, whole grains, lean proteins, and seeds. Their findings reinforce a key principle: when meals are smaller, every bite should deliver maximum nutritional value.
Common side effects of GLP-1 medications include nausea, constipation, and other digestive discomforts.[4] Nuts and dried fruits may offer added dietary support in managing these challenges. Fiber-rich dried fruits can help promote regularity and support gut health. Nuts, meanwhile, are easy to incorporate into small meals or snacks and provide healthy fats and protein that help preserve muscle mass during weight loss.
For anyone using GLP-1 medications —whether for diabetes, weight loss, or both— the goal isn’t just to eat less, but to eat better in smaller portions. That means choosing foods that help you feel full and support steady blood sugar and digestive comfort, while delivering essential nutrients concentrated in smaller servings.
Nuts and dried fruits check all these boxes. As GLP-1 drugs become increasingly popular worldwide, these compact nutrition powerhouses are well positioned to play a valuable role in helping people eat well —even when they’re eating less.
- Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024). Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 9(1), 234.
- Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., & Jones, R. (2025). Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Frontiers in Nutrition, 12, 1566498.
- Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition, 122(1), 344–367.
- Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 134(1), 14–19.